Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ArcelorMittal SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.98 (market cap $29.60B), while ArcelorMittal SA trades at $74.2 (market cap $55.88B). The key difference: ArcelorMittal SA is the larger of the two by market cap, and ArcelorMittal SA pays a 0.81% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MT | |
|---|---|---|
Market Cap | $29.60B | $55.88B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $75.35 |
52-Week Low | $205.48 | $32.44 |
Enterprise Value | $27.56B | $65.45B |
Dividend Yield | — | 0.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
